Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4729799 | 1.00 | MAPT (0.55) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4726650 | 0.86 | NPC1 (0.54) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4726649 | 0.86 | NPC1 (0.54) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4730873 | 0.85 | MAPT (0.67) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4730870 | 0.85 | MAPT (0.67) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL14214470 | 0.85 | MAPT (0.55) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL4729800 | 0.78 | IDO1 (0.55) | MAPTNPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL21390010 | 0.77 | MAPT (0.53) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL5630153 | 0.76 | MAPT (0.44) | MAPTNPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL5632051 | 0.76 | MAPT (0.44) | MAPTNPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-22 | — | — | US | claimed |
| WO-2008036643-A2 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | claimed |
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | MAPT 2706/4885NPC1 2658/4885RAB9A 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.